Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease.

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-10-03 DOI:10.1007/s10787-025-01949-x

Diana Denisse Álvarez-Luquín, Adrián Guevara-Salinas, Edgar Sevilla-Reyes, Jorge Rosas-García, Miriam Bravo-Martinez, Gloria Erandi Pérez-Figueroa, Vera Teresa Vega-Angeles, Dafne Díaz-Rivera, Carlos Castellanos-Barba, Laura Adalid-Peralta

{"title":"Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease.","authors":"Diana Denisse Álvarez-Luquín, Adrián Guevara-Salinas, Edgar Sevilla-Reyes, Jorge Rosas-García, Miriam Bravo-Martinez, Gloria Erandi Pérez-Figueroa, Vera Teresa Vega-Angeles, Dafne Díaz-Rivera, Carlos Castellanos-Barba, Laura Adalid-Peralta","doi":"10.1007/s10787-025-01949-x","DOIUrl":null,"url":null,"abstract":"<p><p>Parkinson's disease is a chronic degenerative disorder characterized by the death of dopaminergic neurons, associated with persistent inflammation in the central nervous system. Immunoregulatory cells are known to play a critical role in controlling inflammation and providing neuroprotection. While dopamine agonists, such as pramipexole and rotigotine, have proven effects on immune cells, their activity on other types of immunoregulatory cells remains unclear. This study aims to elucidate the genetic changes induced by these dopaminergic agonists in immunoregulatory cells (Tregs, CD8regs, Bregs, and the monocyte subpopulations CM, IM, and nCM) and their potential impact on regulation and neuroprotection. All immunoregulatory cell populations studied showed distinct transcriptional profiles regardless of the agonist used for stimulation. Monocytes showed more terms related to neuroprotection on gene ontology analysis. Our results suggest that different agonists induce distinct patterns of gene expression in immunoregulatory cells, affecting different signaling pathways associated with cellular components, biological processes, and molecular functions, mostly associated with suppressor function and with possible effects on neurons. These findings may help us understand and potentially improve the immune effects of current treatments.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-025-01949-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Parkinson's disease is a chronic degenerative disorder characterized by the death of dopaminergic neurons, associated with persistent inflammation in the central nervous system. Immunoregulatory cells are known to play a critical role in controlling inflammation and providing neuroprotection. While dopamine agonists, such as pramipexole and rotigotine, have proven effects on immune cells, their activity on other types of immunoregulatory cells remains unclear. This study aims to elucidate the genetic changes induced by these dopaminergic agonists in immunoregulatory cells (Tregs, CD8regs, Bregs, and the monocyte subpopulations CM, IM, and nCM) and their potential impact on regulation and neuroprotection. All immunoregulatory cell populations studied showed distinct transcriptional profiles regardless of the agonist used for stimulation. Monocytes showed more terms related to neuroprotection on gene ontology analysis. Our results suggest that different agonists induce distinct patterns of gene expression in immunoregulatory cells, affecting different signaling pathways associated with cellular components, biological processes, and molecular functions, mostly associated with suppressor function and with possible effects on neurons. These findings may help us understand and potentially improve the immune effects of current treatments.

查看原文本刊更多论文

普拉克索和罗替戈汀诱导的调节性免疫细胞的遗传变化：对帕金森病治疗的影响

帕金森病是一种以多巴胺能神经元死亡为特征的慢性退行性疾病，与中枢神经系统的持续炎症有关。众所周知，免疫调节细胞在控制炎症和提供神经保护方面发挥着关键作用。虽然多巴胺激动剂，如普拉克索和罗替戈汀，已被证实对免疫细胞有作用，但它们对其他类型的免疫调节细胞的活性尚不清楚。本研究旨在阐明这些多巴胺能激动剂在免疫调节细胞（Tregs、CD8regs、Bregs以及单核细胞亚群CM、IM和nCM）中诱导的遗传变化及其对调节和神经保护的潜在影响。所有研究的免疫调节细胞群都显示出不同的转录谱，而不管使用哪种激动剂进行刺激。单核细胞在基因本体分析中显示出更多与神经保护相关的术语。我们的研究结果表明，不同的激动剂在免疫调节细胞中诱导不同的基因表达模式，影响与细胞成分、生物过程和分子功能相关的不同信号通路，主要与抑制功能相关，并可能对神经元产生影响。这些发现可能有助于我们理解并潜在地改善当前治疗的免疫效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]